Get the Stockscreener App
127.78
2.38%
-3.605
Glaukos Corporation stock is traded at $127.78, with a volume of 1.08M.
It is down -2.38% in the last 24 hours and down -2.08% over the past month.
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
See More
Previous Close:
$131.38
Open:
$125
24h Volume:
1.08M
Relative Volume:
2.20
Market Cap:
$7.11B
Revenue:
$341.73M
Net Income/Loss:
$-158.61M
P/E Ratio:
-47.50
EPS:
-2.69
Net Cash Flow:
$-81.76M
1W Performance:
-6.89%
1M Performance:
-2.08%
6M Performance:
+20.42%
1Y Performance:
+99.75%
1-Day Range:
$124.60
$131.09
1-Week Range:
$124.60
$139.50
52-Week Range:
$59.22
$139.50
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Earnings call: Glaukos reports strong Q3 growth, raises 2024 guidance - Investing.com
Glaukos (NYSE:GKOS) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates - Yahoo Finance
Piper Sandler reaffirms stock target on Glaukos post-Q3 beat - Investing.com
Glaukos price target raised to $145 from $135 at Wells Fargo - TipRanks
BTIG reiterates Buy on Glaukos stock as strong iDose sales support growth outlook - Investing.com
Glaukos Co. (NYSE:GKOS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Glaukos Corp (GKOS) Q3 2024 Earnings Call Highlights: Record Sal - GuruFocus.com
Glaukos Corp (GKOS) Q3 2024 Earnings Call Highlights: Record Sales and Raised Guidance Amid ... - Yahoo Finance
Glaukos Reports Net Sales Increase of 24 Percent in Third Quarter 2024 Behind Strong Glaucoma Sales - Vision Monday
Glaukos reports Q3 adjusted EPS (28c), consensus (48c) - TipRanks
Glaukos Corp. Reports Record Third-Quarter Sales Growth - TipRanks
Glaukos Corp earnings beat by $0.20, revenue topped estimates - Investing.com
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Glaukos: Q3 Earnings Snapshot - San Antonio Express-News
Glaukos Corp (GKOS) Q3 2024 Earnings: EPS of ($0.39) Beats Estimates, Revenue Surges to $96.7 Million - GuruFocus.com
Glaukos Reports Record Sales Despite Net Loss - TipRanks
Glaukos Announces Third Quarter 2024 Financial Results - StockTitan
Glaukos Co. (NYSE:GKOS) Shares Sold by New York State Common Retirement Fund - MarketBeat
Glaukos president sells $316,156 in stock By Investing.com - Investing.com Australia
Glaukos Co. (NYSE:GKOS) COO Sells $316,156.75 in Stock - MarketBeat
Glaukos president sells $316,156 in stock - Investing.com
Earnings To Watch: Glaukos Corp (GKOS) Reports Q3 2024 Result - GuruFocus.com
Possible Bearish Signals With Glaukos Insiders Disposing Stock - Simply Wall St
Creative Planning Purchases 4,937 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Is Glaukos stock ready for a breakout with iDose demand? Jefferies thinks so By Investing.com - Investing.com South Africa
Glaukos stock soars to all-time high of $136.74 amid robust growth By Investing.com - Investing.com South Africa
Glaukos (NYSE:GKOS) Sets New 1-Year HighHere's Why - MarketBeat
Glaukos stock soars to all-time high of $136.74 amid robust growth - Investing.com
Is Glaukos stock ready for a breakout with iDose demand? Jefferies thinks so - Investing.com Canada
Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Glaukos (GKOS) Scheduled to Post Earnings on Monday - MarketBeat
Glaukos Co. (NYSE:GKOS) Stake Boosted by Assenagon Asset Management S.A. - MarketBeat
Taylor Frigon Capital Management LLC Has $3.64 Million Stake in Glaukos Co. (NYSE:GKOS) - MarketBeat
Allspring Global Investments Holdings LLC Has $50.89 Million Stock Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos shares maintain buy rating as Truist sees iDose boosting company’s growth trajectory into 2025 - Investing.com Australia
Long Term Trading Analysis for (GKOS) - Stock Traders Daily
Glaukos (NYSE:GKOS) Upgraded by StockNews.com to "Hold" - MarketBeat
GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa - MSN
Exchange Traded Concepts LLC Buys New Stake in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Corp (GKOS) Stock Price Up 3.09% on Oct 18 - GuruFocus.com
Glaukos eyes FDA approval for ocular therapy after Phase III win - Pharmaceutical Technology
Glaukos shares maintain Overweight rating from Piper Sandler - Investing.com
Glaukos shares maintain Overweight rating from Piper Sandler By Investing.com - Investing.com South Africa
Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety - BioSpace
Glaukos announces positive results in keratoconus treatment trial - Investing.com
Glaukos says Epioxa Phase 3 confirmatory trial meets primary endpoint - TipRanks
Glaukos, Ripple Therapeutics enter licensing agreement - TipRanks
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):